Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

Multiple sclerosis (MS) has more than doubled in recorded prevalence in England from 2000 to 2020, increasing by 6% per year, largely due to improved diagnosis and longer life expectancy, finds a new ...

Patients with newly diagnosed multiple myeloma (NDMM) treated at a specialized clinic have improved outcomes, with median overall survival (OS) of 152 months, according to a research letter published ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

BVd regimen showed significant OS improvement over DVd in relapsed/refractory multiple myeloma, with a predicted median OS of 84 months versus 51 months. BVd achieved higher ORR (83.1% vs 71.3%) and ...

Data from CARTITUDE-4 show that cilta-cel can improve outcomes for patients with lenalidomide-refractory multiple myeloma as early as first relapse. Treatment with ciltacabtagene autoleucel (cilta-cel ...

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction. Treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) conferred ...

Elranatamab significantly prolonged progression-free survival versus daratumumab/pomalidomide/dexamethasone in double-class exposed relapsed/refractory multiple ...

Many of these advances and breakthroughs are the result of decades of work and clinical trials. "When we see such success like this, it is really a marker of all of the work that has been put into ...

Even for the same type of lung cancer, reported 5-year survival rates can vary from 10% to 30%. Patients change their life plans based on these figures, and sometimes even give up on treatment.